Drug-induced Adverse Events
Efficacy and safety of 400 mg efavirenz versus standard 600 mg dose when taken with tenofovir and lamivudine combination in Indian adult patients with HIV-1 infection: An open-label, interventional, randomized, non-inferiority trial
Medicine (Baltimore). 2022 Dec 2;101(48):e31982. doi: 10.1097/MD.0000000000031982.
NO ABSTRACT
PMID:36482530 | DOI:10.1097/MD.0000000000031982
Post COVID-19 vaccination side effects and associated factors among vaccinated health care providers in Oromia region, Ethiopia in 2021
PLoS One. 2022 Dec 8;17(12):e0278334. doi: 10.1371/journal.pone.0278334. eCollection 2022.
NO ABSTRACT
PMID:36480564 | DOI:10.1371/journal.pone.0278334
Qualitative analysis of telephonic comprehensive medication review content and delivery
J Am Pharm Assoc (2003). 2022 Nov 17:S1544-3191(22)00386-7. doi: 10.1016/j.japh.2022.11.006. Online ahead of print.
NO ABSTRACT
PMID:36481091 | DOI:10.1016/j.japh.2022.11.006
A Rare Case of Phentermine-Induced Nonischemic Cardiomyopathy
Cureus. 2022 Nov 5;14(11):e31114. doi: 10.7759/cureus.31114. eCollection 2022 Nov.
NO ABSTRACT
PMID:36479398 | PMC:PMC9720414 | DOI:10.7759/cureus.31114
Phase 1 trial of zolbetuximab in Japanese patients with CLDN18.2+ gastric or gastroesophageal junction adenocarcinoma
Cancer Sci. 2022 Dec 7. doi: 10.1111/cas.15684. Online ahead of print.
NO ABSTRACT
PMID:36478334 | DOI:10.1111/cas.15684
Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity
Diabetes Obes Metab. 2022 Dec 7. doi: 10.1111/dom.14932. Online ahead of print.
NO ABSTRACT
PMID:36478142 | DOI:10.1111/dom.14932
A randomized, phase II study of sequential belimumab and rituximab in primary Sjögren's syndrome
JCI Insight. 2022 Dec 8;7(23):e163030. doi: 10.1172/jci.insight.163030.
NO ABSTRACT
PMID:36477362 | DOI:10.1172/jci.insight.163030
Pneumonitis associated with bortezomib in a patient with multiple myeloma
J Oncol Pharm Pract. 2022 Dec 7:10781552221143789. doi: 10.1177/10781552221143789. Online ahead of print.
NO ABSTRACT
PMID:36476141 | DOI:10.1177/10781552221143789
COVID-19 Vaccine Side Effects among Early-Vaccinated Healthcare Workers: Correspondence
Ethiop J Health Sci. 2022 Nov;32(6):1254. doi: 10.4314/ejhs.v32i6.24.
NO ABSTRACT
PMID:36475261 | PMC:PMC9692152 | DOI:10.4314/ejhs.v32i6.24
COVID-19 Vaccine Hesitancy and its Reasons in Addis Ababa, Ethiopia: A Cross-Sectional Study
Ethiop J Health Sci. 2022 Nov;32(6):1061-1070. doi: 10.4314/ejhs.v32i6.2.
NO ABSTRACT
PMID:36475258 | PMC:PMC9692159 | DOI:10.4314/ejhs.v32i6.2
UGT1A1 Genetic Testing for Irinotecan Should be done before Starting the Treatment, Rather than after the Development of Serious Adverse Drug Reactions
J Coll Physicians Surg Pak. 2022 Dec;32(12):1651-1652. doi: 10.29271/jcpsp.2022.12.1651.
NO ABSTRACT
PMID:36474400 | DOI:10.29271/jcpsp.2022.12.1651
COVID-19 vaccination side effects among the child age group: a large cross-sectional online based survey in Saudi Arabia
BMC Infect Dis. 2022 Dec 6;22(1):911. doi: 10.1186/s12879-022-07905-2.
NO ABSTRACT
PMID:36474174 | PMC:PMC9724422 | DOI:10.1186/s12879-022-07905-2
Immune-related generalised oedema - A new category of adverse events with immune checkpoint inhibitors
Eur J Cancer. 2022 Nov 12;179:28-47. doi: 10.1016/j.ejca.2022.11.001. Online ahead of print.
NO ABSTRACT
PMID:36473326 | DOI:10.1016/j.ejca.2022.11.001
Vaccine hesitancy prospectively predicts nocebo side-effects following COVID-19 vaccination
Sci Rep. 2022 Dec 5;12(1):20018. doi: 10.1038/s41598-022-21434-7.
NO ABSTRACT
PMID:36470896 | DOI:10.1038/s41598-022-21434-7
Research progress in inducing immunogenic cell death of tumor cells
Front Immunol. 2022 Nov 17;13:1017400. doi: 10.3389/fimmu.2022.1017400. eCollection 2022.
NO ABSTRACT
PMID:36466838 | PMC:PMC9712455 | DOI:10.3389/fimmu.2022.1017400
The mechanism and efficacy of GLP-1 receptor agonists in the treatment of Alzheimer's disease
Front Endocrinol (Lausanne). 2022 Nov 17;13:1033479. doi: 10.3389/fendo.2022.1033479. eCollection 2022.
NO ABSTRACT
PMID:36465634 | PMC:PMC9714676 | DOI:10.3389/fendo.2022.1033479
Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
Eur J Gastroenterol Hepatol. 2023 Jan 1;35(1):1-14. doi: 10.1097/MEG.0000000000002471.
NO ABSTRACT
PMID:36468565 | DOI:10.1097/MEG.0000000000002471
Suspected adverse drug reactions of the type 2 antidiabetic drug class dipeptidyl-peptidase IV inhibitors (DPP4i): Can polypharmacology help explain?
Pharmacol Res Perspect. 2022 Dec;10(6):e01029. doi: 10.1002/prp2.1029.
NO ABSTRACT
PMID:36468400 | DOI:10.1002/prp2.1029
COVID-19-associated liver injury, role of drug therapy and management: a review
Egypt Liver J. 2022;12(1):66. doi: 10.1186/s43066-022-00230-y. Epub 2022 Nov 23.
NO ABSTRACT
PMID:36466933 | PMC:PMC9685032 | DOI:10.1186/s43066-022-00230-y
Developing a deep learning natural language processing algorithm for automated reporting of adverse drug reactions
J Biomed Inform. 2022 Dec 1:104265. doi: 10.1016/j.jbi.2022.104265. Online ahead of print.
NO ABSTRACT
PMID:36464227 | DOI:10.1016/j.jbi.2022.104265